JATT Acquisition (JATT) Competitors $1.64 -0.04 (-2.38%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. CRDL, ZURA, BHST, ATOS, MCRB, ANIX, CHRS, CRBP, HLVX, and TCRXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Cardiol Therapeutics (CRDL), Zura Bio (ZURA), BioHarvest Sciences (BHST), Atossa Genetics (ATOS), Seres Therapeutics (MCRB), ANIXA BIOSCIENCES (ANIX), Coherus Oncology (CHRS), Corbus Pharmaceuticals (CRBP), HilleVax (HLVX), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors Cardiol Therapeutics Zura Bio BioHarvest Sciences Atossa Genetics Seres Therapeutics ANIXA BIOSCIENCES Coherus Oncology Corbus Pharmaceuticals HilleVax TScan Therapeutics JATT Acquisition (NYSE:JATT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Does the media refer more to JATT or CRDL? In the previous week, Cardiol Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for JATT Acquisition. Cardiol Therapeutics' average media sentiment score of 0.94 beat JATT Acquisition's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Cardiol Therapeutics Positive Do insiders and institutionals have more ownership in JATT or CRDL? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, JATT or CRDL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ACardiol TherapeuticsN/AN/A-$26.77M-$0.34-4.49 Is JATT or CRDL more profitable? JATT Acquisition's return on equity of -49.58% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Cardiol Therapeutics N/A -209.63%-141.09% Do analysts prefer JATT or CRDL? Cardiol Therapeutics has a consensus target price of $8.00, indicating a potential upside of 424.59%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCardiol Therapeutics beats JATT Acquisition on 6 of the 11 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$28.29M$271.65M$5.71B$20.96BDividend YieldN/AN/A4.70%3.59%P/E RatioN/AN/A28.2128.32Price / SalesN/A352.51471.0057.08Price / Cash27.0822.4425.1818.21Price / Book-3.0912.138.474.70Net Income$6.85M-$106.40M$3.25B$992.76M7 Day Performance-14.14%0.15%2.75%1.89%1 Month Performance56.19%20.50%10.80%4.54%1 Year Performance-57.84%8.68%34.12%9.62% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.64-2.4%N/A-57.8%$28.29MN/A0.003High Trading VolumeCRDLCardiol Therapeutics2.0494 of 5 stars$1.44+2.9%$8.00+455.6%-36.0%$115.71MN/A-4.2420Gap UpZURAZura Bio3.3412 of 5 stars$1.69+0.6%$14.33+748.1%-57.8%$114.87MN/A-2.413BHSTBioHarvest SciencesN/A$7.29+5.7%$13.67+87.5%N/A$113.39M$25.19M-14.58N/AHigh Trading VolumeATOSAtossa Genetics2.7781 of 5 stars$0.89+3.2%$6.17+595.7%-42.9%$111MN/A-4.228Positive NewsMCRBSeres Therapeutics3.2077 of 5 stars$13.09+5.6%$73.67+462.8%-45.0%$108.19M$126.32M-2.85330Gap UpANIXANIXA BIOSCIENCES2.8313 of 5 stars$3.38+1.2%$9.00+166.3%+5.6%$107.42M$210K-8.895Positive NewsCHRSCoherus Oncology3.8512 of 5 stars$0.98+6.1%$4.68+378.6%-39.5%$106.93M$272.25M-0.87330Gap UpCRBPCorbus Pharmaceuticals4.8383 of 5 stars$8.79+1.0%$50.88+478.8%-84.1%$106.46MN/A-2.0840HLVXHilleVax1.9683 of 5 stars$2.10-0.5%$2.00-4.8%+13.8%$105.80MN/A-0.9820Positive NewsTCRXTScan Therapeutics3.5775 of 5 stars$1.86+0.5%$7.80+319.4%-73.5%$104.69M$2.82M-1.71100News Coverage Related Companies and Tools Related Companies CRDL Alternatives ZURA Alternatives BHST Alternatives ATOS Alternatives MCRB Alternatives ANIX Alternatives CHRS Alternatives CRBP Alternatives HLVX Alternatives TCRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
